Abstract:Therapeutic strategies to protect the ischemic myocardium have been studied extensively. Reperfusion is the definitive treatment for acute coronary syndromes, especially acute myocardial infarction; however, reperfusion has the potential to exacerbate lethal tissue injury, a process termed "reperfusion injury." Ischemia/reperfusion injury may lead to myocardial infarction, cardiac arrhythmias, and contractile dysfunction. Ischemic preconditioning of myocardium is a well described adaptive response in which brief exposure to ischemia/reperfusion before sustained ischemia markedly enhances the ability of the heart to withstand a subsequent ischemic insult. Additionally, the application of brief repetitive episodes of ischemia/reperfusion at the immediate onset of reperfusion, which has been termed "postconditioning," reduces the extent of reperfusion injury. Ischemic pre- and postconditioning share some but not all parts of the proposed signal transduction cascade, including the activation of survival protein kinase pathways. Most experimental studies on cardioprotection have been undertaken in animal models, in which ischemia/reperfusion is imposed in the absence of other disease processes. However, ischemic heart disease in humans is a complex disorder caused by or associated with known cardiovascular risk factors including hypertension, hyperlipidemia, diabetes, insulin resistance, atherosclerosis, and heart failure; additionally, aging is an important modifying condition. In these diseases and aging, the pathological processes are associated with fundamental molecular alterations that can potentially affect the development of ischemia/reperfusion injury per se and responses to cardioprotective interventions. Among many other possible mechanisms, for example, in hyperlipidemia and diabetes, the pathological increase in reactive oxygen and nitrogen species and the use of the ATP-sensitive potassium channel inhibitor insulin secretagogue antidiabetic drugs and, in aging, the reduced expression of connexin-43 and signal transducer and activator of transcription 3 may disrupt major cytoprotective signaling pathways thereby significantly interfering with the cardioprotective effect of pre- and postconditioning. The aim of this review is to show the potential for developing cardioprotective drugs on the basis of endogenous cardioprotection by pre- and postconditioning (i.e., drug applied as trigger or to activate signaling pathways associated with endogenous cardioprotection) and to review the evidence that comorbidities and aging accompanying coronary disease modify responses to ischemia/reperfusion and the cardioprotection conferred by preconditioning and postconditioning. We emphasize the critical need for more detailed and mechanistic preclinical studies that examine car-dioprotection specifically in relation to complicating disease states. These are now essential to maximize the likelihood of successful development of rational approaches to therapeutic protection for the majority of patients with ischemic heart disease who are aged and/or have modifying comorbid conditions.

Mechanism of Cardioprotection by Early Ischemic Preconditioning

Involvement of the Mitochondrial Calcium Uniporter in Cardioprotection by Ischemic Preconditioning

Cardioprotection of Ischemic Postconditioning Against Ischemia/reperfusion Injury in Isolated Rat Hearts

Ischemic Preconditioning Delays Ischemia-Induced Cellularelectrical Uncoupling in Rat Heart

Inhibition of Mitochondrial Permeability Transition Pore Opening Mediated by Kappa‐opioid Receptor in Cardioprotection by Remote Preconditioning

Activation of Mitochondrial ATP-sensitive Potassium Channels Delays Ischemia-Induced Cellular Uncoupling in Rat Heart.

Novel Rapid‐Multiple‐Short‐Cycle Preconditioning Stimuli Induces Robust Cardioprotective Signaling Mechanisms and Protects the Heart against in vivo Ischemia Reperfusion Injury: An Effective Approach with Clinical Justification

Immediate Early Response Gene X-1 (IEX-1) Mediates Ischemic Preconditioning-Induced Cardioprotection in Rats

Ischemic Preconditioning Inhibits Mitochondrial Permeability Transition Pore Opening Through the PTEN/PDE4 Signaling Pathway.

Post-conditioning Protects Rat Cardiomyocytes Via PKCε-mediated Calcium-Sensing Receptors

Cardioprotection of Ischemic Postconditioning and Pharmacological Post-Treatment with Adenosine or Acetylcholine.

Remote Cardioprotection by Transfer of Coronary Effluent from Ischemic Preconditioned Rabbit Heart Preserves Mitochondrial Integrity and Function via Adenosine Receptor Activation

Myocardial protective effect of ischemic preconditioning and its mechanism in immature rabbit heart

The Mitochondrial Ca2+-activated K+ Channel Contributes to Cardioprotection by Limb Remote Ischemic Preconditioning in Rat

Cardioprotective PKG-independent NO signaling at reperfusion

Ischemic Postconditioning Protects Myocardium from Ischemia/reperfusion Injury Through Attenuating Endoplasmic Reticulum Stress.

Ischemic preconditioning affects phosphosites and accentuates myocardial stunning while reducing infarction size in rats

Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning

The Effect of Ischemic Preconditioning on Myocardium Injury and Electrophysiology Change in Isolated Langendorff-perfused Rabbit Heart

Abstract P077: Ischemic Preconditioning Improves Postischemic Cardiac Function by Preserving PTEN Activity

Cardioprotection of ischemic preconditioning in rats involves upregulating adiponectin.